Protective Effect of miR-204 on Doxorubicin-Induced Cardiomyocyte Injury via HMGB1.
Youyou DuGuanghui LiuLuosha ZhaoRui YaoPublished in: Oxidative medicine and cellular longevity (2020)
The toxicity of doxorubicin (DOX) limits its clinical application. Nevertheless, at present, there is no effective drug to prevent DOX-induced cardiac injury. miR-204 is a newly discovered miRNA with many protective effects on cardiovascular diseases. However, little research has been done on the effects of miR-204 on DOX-induced cardiac injury. Our study is aimed at investigating the effect of miR-204 on DOX-induced myocardial injury. An adenoassociated virus system was used to achieve cardiac-specific overexpression of miR-204. Two weeks later, the mice were intraperitoneally injected with DOX (15 mg/kg) to induce cardiac injury. H9c2 myocardial cells were used to validate the role of miR-204 in vitro. Our study showed that miR-204 expression was decreased in DOX-treated hearts. miR-204 overexpression improved cardiac function and alleviated cardiac inflammation, apoptosis, and autophagy induced by DOX. In addition, our results showed that miR-204 prevented DOX-induced injury in cardiomyocytes by directly decreasing HMGB1 expression. Moreover, the overexpression of HMGB1 could offset the protective effects of miR-204 against DOX-induced cardiac injury. In summary, our study showed that miR-204 protected against DOX-induced cardiac injury via the inhibition of HMGB1, and increasing miR-204 expression may be a new treatment option for patients with DOX-induced cardiac injury.
Keyphrases
- cell proliferation
- long non coding rna
- high glucose
- long noncoding rna
- poor prognosis
- diabetic rats
- left ventricular
- oxidative stress
- drug induced
- cardiovascular disease
- emergency department
- endothelial cells
- cell death
- type diabetes
- binding protein
- drug delivery
- signaling pathway
- induced apoptosis
- insulin resistance
- atrial fibrillation
- cardiovascular risk factors
- cardiovascular events
- angiotensin ii